Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINE ® compound CX717 achieved ...
Original post: Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints in ... - MSN MoneyCentral
- Recent posts
- Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints in ... - MSN MoneyCentral
- P'cola physician arrested for 'doctor shopping' - Pensacola News Journal
- Update in Pain Management and Risk Assessment
- Natural Pain Management: Exercise & Chronic Pain
- Program to focus on pain management
- Does Death With Dignity law deserve voters' approval? - Columbian
- Pain-management doctor charged in drug probe - Pensacola News Journal
- Sensex tumbles, biggest weekly fall in 18yrs - Reuters India
- Somatic Systems, Inc. to Discuss Contracts With US Military - Market Wire
- Pain management techniques
- Orthopedic hospital opens doors for patients - Birmingham Business Journal
- Transdel Enrolls First Patient For Ketotransdel(TM) Phase 3 ...
- International Conference on Pain and Chemical Dependency Adds October ... - Phramalive.com
- Many cancer patients forgo painkillers - Saskatoon Star Phoenix
- Disparities in Pain Management: An Expert Interview With Carmen R ... - Medscape News
- Comment on Chronic Pain Management for Body Pain and Mental Stress ...
- American Society for Pain Management Nursing (ASPMN)
- As One Of The Largest Pain Management Facilities In Pinellas ...
- RBC Life Sciences Names Veteran Strategic Growth Leader, Robert Kaiser ... - MSN MoneyCentral
- September is Pain Awareness Month - Forbes